Cagrilintide 10MG
Cagrilintide is a long-acting amylin receptor agonist (non-selective for amylin and calcitonin receptors). Phase 3 trials (including monotherapy data) show promising weight-loss results, with monotherapy achieving around 11-12% average reduction in some studies, and far stronger effects in combination. It's being positioned as a next-generation option for enhanced satiety beyond GLP-1 agonists alone.
Research Use Only.
Non-returnable
Choose Quantity :
Product Information
Product Details
Who Might Use It in Research?
- Researchers exploring advanced appetite suppression and satiety mechanisms
- Those studying amylin pathway roles in obesity and metabolic regulation
- Investigators examining complementary effects to GLP-1 agonists (e.g., in CagriSema analogs or blends)
- Scientists focused on next-generation weight-loss compounds and body composition optimization
How Does It Work?
- Enhances satiety and reduces food intake via amylin/calcitonin receptors in the brain (especially brainstem and hypothalamus)
- Slows gastric emptying to prolong post-meal fullness
- Suppresses postprandial glucagon release to support blood sugar stability
- Provides synergistic benefits when combined with GLP-1 agonists for amplified appetite control
What Researchers Typically Observe?
- Monotherapy: ~11.8% average weight loss over 68 weeks (vs. ~2.3% placebo) in phase 3 obesity trials
- Significant reductions in food intake, meal size/frequency, and cardiometabolic markers (e.g., lipids, blood pressure)
- Around 1 in 3 participants achieve ≥15% weight loss with monotherapy